Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Asahi Glass Licenses ASPEX to Diversa
January 14, 2002
- Olympus ProMarketing: Semiconductor Laser Device
January 14, 2002
- Roche Was Selected to Strengthen R&D Ability: Mr Nagayama of Chugai
January 14, 2002
- Shimadzu: Floor-Mounted Type Angiographic C-arm Support MH-300
January 14, 2002
- Dainippon Joins Tsumura in Development of Ca Antagonist
January 14, 2002
- Princeton Note Litigation Settled
January 14, 2002
- ATOL-MI Transferred to Yamashita Ikakiki
January 14, 2002
- Expert Stresses Promotion of Technology Transfer: JPMA Symposium
January 14, 2002
- Sequelae of Cerebral Hemorrhage Deleted from Ketas Indications
January 14, 2002
- To Play a Meaningful Social Role, Become Independent, and Increase Profitability
January 14, 2002
- Long-listed Drugs Account for up to 60% of Total Sales: Top 10 Companies
January 14, 2002
- REGULATORY NEWS IN BRIEF
December 31, 2001
- Kissei, Novartis Make Alliance for Agent for Glaucoma
December 31, 2001
- Sankyo to Copromote CS-866 with Forest Laboratories in US
December 31, 2001
- S-P to Increase Its MRs to 600 to Detail Ribavirin
December 31, 2001
- GSK's Flutide Diskus Included in NHI Price List
December 31, 2001
- The Year 2001 in Retrospect:
December 31, 2001
- BUSINESS NEWS IN BRIEF
December 31, 2001
- Innovation and Reward - Contributing to a Healthy and Growing Economy
December 31, 2001
- Takara Shuzo Develops New Gene Transfer Technology, rPIC Method
December 31, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…